US Patent

US8222292 — Liquid cannabinoid formulations

Composition of Matter · Assigned to Insys Therapeutics Inc · Expires 2028-08-06 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects liquid formulations of the active substance dronabinol, which is used in the drug Marinol.

USPTO Abstract

Oral cannabinoid formulations, including an aqueous-based oral dronabinol solution, that are stable at room or refrigerated temperatures and may possess improved in vivo absorption profiles with faster onset and lower inter-subject variability.

Drugs covered by this patent

Patent Metadata

Patent number
US8222292
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-08-06
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Insys Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.